Melanoma

What do all the mutations mean?

Elizabeth J. Davis, Douglas B. Johnson, Jeffrey Alan Sosman, Sunandana Chandra

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both “driver” and “passenger” genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.

Original languageEnglish (US)
Pages (from-to)3490-3499
Number of pages10
JournalCancer
Volume124
Issue number17
DOIs
StatePublished - Sep 1 2018

Fingerprint

Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Ultraviolet Rays
Therapeutics
Genes
Neoplasms

Keywords

  • BRAF
  • KIT
  • NRAS
  • cyclin-dependent kinase inhibitor 2A (CDKN2A)
  • melanoma
  • mutation
  • programmed cell death protein 1 (PD-1)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Davis, Elizabeth J. ; Johnson, Douglas B. ; Sosman, Jeffrey Alan ; Chandra, Sunandana. / Melanoma : What do all the mutations mean?. In: Cancer. 2018 ; Vol. 124, No. 17. pp. 3490-3499.
@article{57681e428be74a6d8f312f943b6d8094,
title = "Melanoma: What do all the mutations mean?",
abstract = "Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both “driver” and “passenger” genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.",
keywords = "BRAF, KIT, NRAS, cyclin-dependent kinase inhibitor 2A (CDKN2A), melanoma, mutation, programmed cell death protein 1 (PD-1)",
author = "Davis, {Elizabeth J.} and Johnson, {Douglas B.} and Sosman, {Jeffrey Alan} and Sunandana Chandra",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/cncr.31345",
language = "English (US)",
volume = "124",
pages = "3490--3499",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "17",

}

Melanoma : What do all the mutations mean? / Davis, Elizabeth J.; Johnson, Douglas B.; Sosman, Jeffrey Alan; Chandra, Sunandana.

In: Cancer, Vol. 124, No. 17, 01.09.2018, p. 3490-3499.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Melanoma

T2 - What do all the mutations mean?

AU - Davis, Elizabeth J.

AU - Johnson, Douglas B.

AU - Sosman, Jeffrey Alan

AU - Chandra, Sunandana

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both “driver” and “passenger” genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.

AB - Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both “driver” and “passenger” genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.

KW - BRAF

KW - KIT

KW - NRAS

KW - cyclin-dependent kinase inhibitor 2A (CDKN2A)

KW - melanoma

KW - mutation

KW - programmed cell death protein 1 (PD-1)

UR - http://www.scopus.com/inward/record.url?scp=85054917728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054917728&partnerID=8YFLogxK

U2 - 10.1002/cncr.31345

DO - 10.1002/cncr.31345

M3 - Review article

VL - 124

SP - 3490

EP - 3499

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 17

ER -